Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer

NCT01347645 | Terminated Phase 1 Results

• 2 other identifiers: E7820-7022011-001762-18
• Study Type: interventional
• Target: 82
• Locations: 6 countries
• Sites: 38

Brief Summary

The purpose of the Phase Ib portion is to find out the highest dose of study drug that can safely be given when tested in a small group of subjects. The purpose of the Phase II portion is to find out how safe the study drug is when taken at the highest dose in a larger group of subjects.

Conditions

Colon Cancer; Rectal Cancer

Keywords

locally advanced; metastatic colon; rectal cancer

Outcome Measures

Primary Outcomes (2)

• Phase 1b: Maximum Tolerated Dose (MTD) of E7820 With Irinotecan as Per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0

  MTD: maximum dose that was determined to be safe and tolerable for Phase 2.If two dose limiting toxicities (DLTs) occurred at any dose level,MTD: preceding dose/intermediate dose.DLT was graded according to CTCAE v4.0. Includes \>= Grade 3(G3) peripheral neuropathy,\>=G3 nausea/vomiting despite optimal anti-emetic treatment, any other non-hematologic toxicity of \>=G3(except alopecia, single abnormal laboratory values Investigator judged unlikely related to study therapy, had no clinical correlate, resolved in 7 days, hypersensitivity reaction to any of compounds),Grade 4 neutropenia lasting over 7 days,febrile neutropenia(defined as fever \>=38.5 degrees Celsius with absolute neutrophil count below 1.0\*10\^9 per liter, G3 thrombocytopenia with nontraumatic bleeding(without therapeutic systemic anticoagulation)requiring platelet transfusion,Grade 4 thrombocytopenia (with/without nontraumatic bleeding),any study drug-related death,other toxicity dose escalation committee believed to be DLT.

  Up to 12 cycles (each cycle length =14 days)

• Phase 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

  TEAE is defined as an adverse event that had an onset date, or a worsening in severity on or after the first dose of study drug up to the end of the study. Number of participants with TEAEs are reported based on safety assessments of laboratory tests, physical examination, examining bowel movements, regular measurement of vital signs, eastern cooperative oncology group-performance status and electrocardiogram parameter values. SAE is any untoward medical occurrence that at any dose: resulted in death; life threatening required inpatient hospitalization; resulted in persistent, significant disability; is congenital anomaly/birth defect or medically important due to other reasons than above mentioned criteria. Number of participants with TEAEs and SAEs were reported.

  From the first dose of study drug up to 28 days after last dose (Up to 1 year and 3 months)

Secondary Outcomes (4)

• Phase 2: Progression Free Survival (PFS)

  From date of randomization up to 1 year and 2 months

• Phase 2: Overall Survival (OS)

  From date of randomization up to 1 year and 2 months

• Phase 2: Time to Progression (TTP)

  From date of randomization up to 1 year and 2 months

• Phase 2: Percentage of Participants With Overall Response

  From date of randomization up to 1 year and 2 months

Study Arms (2)

1

ACTIVE COMPARATOR

Experimental Irinotecan plus E7820

Drug: E7820

2

ACTIVE COMPARATOR

FOLFIRI alone

Drug: FOLFIRI

Interventions

FOLFIRI DRUG

Comparator dose and mode of administration The FOLFIRI regimen consists of irinotecan at 180 mg/m2 (IV infusion) on Day 1 of each 14-day cycle, leucovorin at 200 mg/m2 (400 mg/m2 if using d,l-racemic mixture of leucovorin) by IV infusion on Day 1 of each cycle, and 5-FU at 400 mg/m2 as an IV bolus injection followed by a total of 2400 mg/m2 by continuous IV infusion over 46 hours over Days 1 and 2 via an ambulatory programmable pump (the use of an ambulatory pump is optional).

2

E7820 DRUG

Test product: dose and mode of administration: E7820 is administered orally in tablet form once daily, every day of each 14-day treatment cycle. For the Phase Ib portion, the doses will be 40 mg/day, 70 mg/day, and 100 mg/day, and for the Pase II portion, the dose will be the MTD in combination with Irinotecan, as determined during the Phase ib portion of the study. The irinotecan regimen consists of an irinotecan dose of 180 mg/m2 by IV infusion once every 2 weeks (Day 1 of each 14-day cycle).

1

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients may be entered in the study only if they meet all of the following criteria:
• Male or female patient greater than or equal to 18 years of age;
• Histologically or cytologically confirmed nonresectable locally advanced or metastatic colorectal adenocarcinoma;
• Patients must have failed a first-line chemotherapy regimen for nonresectable locally advanced or mCRC (first-line 5-FU-based therapies, including but not limited to FOLFOX, FOLFOX 4, mFOLFOX6, CapeOX, single-agent capecitabine, infusional 5-FU, or other chemotherapies. Bevacizumab, cetuximab, panitumumab, and EGFR inhibitors are allowed. Prior treatment with irinotecan or FOLFIRI is not allowed for Phase II). For Phase Ib only, up to 3 prior therapies are allowed (including non-irinotecan containing therapies and adjuvant therapy);
• At least 1 site of measurable disease by the Response Evaluation Criteria in Solid Tumors (RECIST version 1.1) criteria;
• Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of less than or equal to 2;
• Patients must have adequate renal function as evidenced by serum creatinine less than 2 mg/dL and creatinine clearance greater than 50 mL/minute per the Cockcroft and Gault formula;
• Patients must have adequate bone marrow function as evidenced by absolute neutrophil count (ANC) greater than or equal to 1.5 x 109/L, platelets greater than100 x 109/L, hemoglobin greater than or equal to 9.0 g/dL (a hemoglobin less than 9.0 g/dL at Screening is acceptable if it is corrected to greater than or equal to 9 g/dL by growth factor or transfusion prior to the first dose);
• Patients must have adequate liver function as evidenced by bilirubin less than or equal to 1.5 times the upper limit of the normal range (ULN), and alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) less than or equal to 3 X ULN (in the case of liver metastases, less than or equal to 5 X ULN).If there are bone metastases, liver-specific alkaline phosphatase may be separated from the total and used to assess liver function instead of total alkaline phosphatase;
• For patients with hypertension, it must be well controlled. If a patient presents with poorly controlled hypertension, defined as a mean systolic blood pressure greater than or equal to140 mm Hg or mean diastolic blood pressure greater than or equal to 90 mm Hg,antihypertensive medication(s) should be initiated or adjusted with a goal to control the blood pressure less than 140/90 mm Hg. Blood pressure must be reassessed on 2 occasions, consecutively, that are separated by a minimum of 24 hours;
• Male or female patients of child-producing potential must agree to use double barrier contraception, oral contraceptives, or avoidance of pregnancy measures during the study and for 90 days after the last day of treatment;
• Females of childbearing potential must have a negative serum pregnancy test at Screening;
• Females may not be breastfeeding; Ability to understand and willingness to sign a written informed consent.

You may not qualify if:

• Received chemotherapy, targeted therapy, radiotherapy, surgery, immunotherapy, or treatment in another clinical study within the 30 days prior to commencing study treatment or have not recovered from side effects of all treatment-related toxicities to Grade less than or equal to 1, except for peripheral neuropathy (Grade 1 and Grade 2 are permitted) and alopecia;
• Previously received irinotecan or irinotecan derivatives in Phase II (irinotecan-containing regimens are allowed in Phase Ib);
• Previously received anti-alpha 2 integrin therapy;
• History of other malignancies except: (1) adequately treated basal or squamous cell carcinoma of the skin; (2) curatively treated in situ carcinoma of the uterine cervix; or (3) other curatively treated solid tumor with no evidence of disease for greater than or equal to 5 years;
• Presence of brain metastases, unless the patient has received adequate treatment at least 4 weeks prior to randomization, and is stable, asymptomatic, and off steroids for at least 4 weeks prior to randomization;
• Are currently receiving any other anticancer treatment;
• Serious non-healing wound, ulcer, or active bone fracture;
• Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1, or anticipation of need for a major surgical procedure during the course of the study;
• Refractory nausea and vomiting, malabsorption, significant bowel resection, or any other medical condition that would preclude adequate absorption or result in the inability to take oral medication;
• Significant cardiovascular impairment (history of congestive heart failure New York Heart Association \[NYHA\] Grade greater than 2, unstable angina or myocardial infarction within the past 6 months, or serious cardiac arrhythmia);
• Active hemoptysis (defined as bright red blood of 1/2 teaspoon or more) within the 30 days prior to study entry;
• Current or recent use (within 7 days) of full-dose warfarin (except low-dose warfarin as required to maintain patency of pre-existing, permanent indwelling IV catheters). For patients receiving warfarin, International Normalization Ratio (INR) should be less than 1.5. Patients may have prophylactic use of low molecular weight heparin; however, therapeutic use of heparin or low molecular weight heparin is not acceptable;
• History of bleeding diathesis or coagulopathy;
• Any history of cerebral vascular accident, transient ischemic attack, or Grade greater than or equal to 2 peripheral vascular disease, unless they have had no evidence of active disease for at least 6 months prior to randomization;
• Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 1, unless affected area has been removed surgically;

Sponsors & Collaborators

• Eisai Inc.: lead
• PharmaBio Development Inc.: collaborator

Study Sites (38)

Unknown Facility

Birmingham, Alabama, 35294, United States

Location

Unknown Facility

West Palm Beach, Florida, 33401, United States

Location

Unknown Facility

Atlanta, Georgia, 30341, United States

Location

Unknown Facility

Ann Arbor, Michigan, 48109, United States

Location

Unknown Facility

Berkeley Heights, New Jersey, 7922, United States

Location

Unknown Facility

Bismarck, North Dakota, 58501, United States

Location

Unknown Facility

Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

Location

Unknown Facility

La Rioja, LA Rioha, Argentina

Location

Unknown Facility

Rosario, Santa Fe Province, Argentina

Location

Unknown Facility

Córdoba, Argentina

Location

Unknown Facility

Coffs Harbour, New South Wales, 2450, Australia

Location

Unknown Facility

Concord, New South Wales, 2139, Australia

Location

Unknown Facility

Townsville, Queensland, 4814, Australia

Location

Unknown Facility

Elizabeth Vale, South Australia, 5112, Australia

Location

Unknown Facility

Kurralta Park, South Australia, 5035, Australia

Location

Unknown Facility

Woodville South, South Australia, 5011, Australia

Location

Unknown Facility

Carlton, Victoria, 3053, Australia

Location

Unknown Facility

Clayton, Victoria, 3168, Australia

Location

Unknown Facility

Epping, Victoria, 3076, Australia

Location

Unknown Facility

Frankston, Victoria, 3199, Australia

Location

Unknown Facility

Wodonga, Victoria, 3690, Australia

Location

Unknown Facility

Belo Horizonte, Minas Gerais, Brazil

Location

Unknown Facility

Novo Hamburgo, Rio Grande do Sul, Brazil

Location

Unknown Facility

Passo Fundo, Rio Grande do Sul, Brazil

Location

Unknown Facility

Port Alegre, Rio Grande do Sul, Brazil

Location

Unknown Facility

Porto Alegre, Rio Grande do Sul, Brazil

Location

Unknown Facility

Jaú, São Paulo, Brazil

Location

Unknown Facility

Rio de Janeiro, Brazil

Location

Unknown Facility

Arkhangelsk, 163045, Russia

Location

Unknown Facility

Chelyabinsk, 454087, Russia

Location

Unknown Facility

Moscow, 115478, Russia

Location

Unknown Facility

Saint Petersburg, 195067, Russia

Location

Unknown Facility

Saint Petersburg, 197758, Russia

Location

Unknown Facility

Sochi, 354057, Russia

Location

Unknown Facility

Dnipropetrovsk, 49102, Ukraine

Location

Unknown Facility

Kharkiv, 61024, Ukraine

Location

Unknown Facility

Kharkiv, 61037, Ukraine

Location

Unknown Facility

Uzhhorod, 88000, Ukraine

Location

MeSH Terms

Conditions

Colonic Neoplasms; Rectal Neoplasms

Interventions

IFL protocol; N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzene-sulfonamide

Condition Hierarchy (Ancestors)

Colorectal Neoplasms; Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Rectal Diseases

Results Point of Contact

• Title: Eisai Medical Information
• Organization: Eisai Inc.

esi_oncmedinfo@eisai.com

+1-888-274-2378

Study Officials

• Harish Dave

  Quintiles, Inc.

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 28, 2011
• First Posted: May 4, 2011
• Study Start: September 30, 2011
• Primary Completion: June 22, 2015
• Study Completion: June 22, 2015
• Last Updated: June 22, 2023
• Results First Posted: November 25, 2022

Record last verified: 2023-06

Locations

RU (6); UA (4); AR (4); BR (7); US (6); AU (11)